Seaport Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Seaport Therapeutics's estimated annual revenue is currently $8.5M per year.
- Seaport Therapeutics's estimated revenue per employee is $155,000
- Seaport Therapeutics's total funding is $330M.
Employee Data
- Seaport Therapeutics has 55 Employees.
- Seaport Therapeutics grew their employee count by 5400% last year.
Seaport Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-founder, Chief Scientific Officer | Reveal Email/Phone |
2 | Founder and Board Chair | Reveal Email/Phone |
3 | Founder and Board Chair | Reveal Email/Phone |
4 | Co-Founder and Chief Scientific Officer | Reveal Email/Phone |
5 | Co-founder, Sr. VP Platform | Reveal Email/Phone |
6 | Chief Operating Officer | Reveal Email/Phone |
7 | Chief Operating Officer | Reveal Email/Phone |
8 | Chief Financial Officer | Reveal Email/Phone |
9 | Head Quality Operations | Reveal Email/Phone |
10 | VP, Head Biometrics | Reveal Email/Phone |
Seaport Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Seaport Therapeutics?
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. We have a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. We are led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. \n\nFor more information, please visit www.seaporttx.com or connect with us on X (formerly Twitter) @SeaportTx
keywords:N/A
$330M
Total Funding
55
Number of Employees
$8.5M
Revenue (est)
5400%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 55 | -24% | N/A |
#2 | $13.4M | 55 | 6% | N/A |
#3 | $10.1M | 55 | -15% | N/A |
#4 | $11.2M | 55 | 4% | N/A |
#5 | $6.9M | 55 | 49% | $32M |